
RRx-001 Oncology Program
Normally, side effects from many oncology medications lead to discontinuation, dose reduction, non-compliance, delays, and pipeline development terminations. In cancer, improved outcomes are related to dose intensity (DI), where patients that receive higher dose intensities experience better overall survival (OS), progression-free survival (PFS), and disease-free survival than patients that receive lower DI levels. Clinical studies suggest that as an NLRP3 inflammasome inhibitor RRx-001 may not only increase the activity of chemotherapy, radiotherapy, and immunotherapy but also decrease their various toxicities including checkpoint inhibitor induced colitis.

Anti-tumor Mechanism of RRx-001

The Inflammasome
Regulating chronic inflammation
“RRx-001 inhibition of the inflammasome represents an exciting potential in the treatment and prevention of chronic inflammation driven diseases”

RICHARD GORDON, Ph.D., DABT
Chief Neuroscience Collaborator



The neuroprotective effects of RRx-001
With funding from The Michael J. Fox Foundation for Parkinson’s Research and Shake it Up Australia, we’re exploring how RRx-001’s inhibition of the inflammasome may reduce or reverse symptoms of Parkinson’s and other neurodegenerative diseases. Led by Dr. Richard Gordon at The University of Queensland in Brisbane, Australia, this collaboration studies how RRx-001 binds to cysteines found in immune and red blood cells, promoting protective cellular responses through induction of the Nrf2 pathway and inhibition of the NLRP3 inflammasome.

RICHARD GORDON, Ph.D., DABT
Chief Neuroscience Collaborator
Dr Richard Gordon leads the Translational Neuroscience Laboratory at The University of Queensland and has a career track record of research in neuroinflammation. His research program aims to develop new therapeutic strategies for the treatment Parkinson’s disease and other neurodegenerative disorders, with a focus on targeting chronic immune and inflammasome activation which drives neurodegeneration. Dr Gordon’s research has contributed to groundbreaking advances in the field neuroinflammation, including most recently, the discovery inflammasome activation in PD as a key driver of synuclein pathology and disease progression. He also Dr Gordon is a board-certified Toxicologist with the American Board of Toxicology (ABT). He is also a Science Ambassador for the World Parkinson’s Coalition and has served on the Gene Technology Technical Advisory Committee (GTTAC) for the Department of Health for the Australian Federal Government.


Chief Financial Officer


CHRIS LARSON,
M.D. Ph.D.
Vice President of Viral Therapy

MEAGHAN STIRN,
M.B.A
Controller & VP of Special Projects

SCOTT CAROEN
Senior Director of Operations & Corporate Development

Rajan Kumar
ESQ
Chief Executive Officer & Chief Scientific Office

Control inflammation & control the disease
RRx-001 inhibits the inflammasome


Chief Financial Officer


CHRIS LARSON,
M.D. Ph.D.
Vice President of Viral Therapy

MEAGHAN STIRN,
M.B.A
Controller & VP of Special Projects

SCOTT CAROEN
Senior Director of Operations & Corporate Development

Rajan Kumar
ESQ
Chief Executive Officer & Chief Scientific Office

Control inflammation & control the disease
RRx-001 inhibits the inflammasome
SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University
Stanford Hospital and Clinics, Lucile Packard Children’s Hospital
THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan
Isadore Lampe Professor of Radiation Oncology
KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School
Physician, Oncology, Brigham And Women’s Hospital
SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University
Stanford Hospital and Clinics, Lucile Packard Children’s Hospital
THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan
Isadore Lampe Professor of Radiation Oncology
KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School
Physician, Oncology, Brigham And Women’s Hospital